Premarket Approval Information - Devices
Product: NucliSens HIV-1 QT
Applicant: bioMerieux, Inc., Durham, NC
PMA number: BP010001/0
Indication for Use: in conjunction with clinical presentation and other laboratory markers of disease progression for prognostic assessment of HIV-1 infected patients, and for monitoring the effects of anti-retroviral therapy by serial measurements of plasma HIV-1 RNA for pediatric and adult patients with baseline viral loads greater than 93,000 and 28,000 copies of HIV-1 viral RNA/mL respectively
Approval Date: 11/19/2001
Letter -
(Text)
Label - (PDF)
Summary - (PDF)
|